Literature DB >> 35098800

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.

Juan Esteban Garcia-Robledo1, Rafael Rosell2, Alejandro Ruíz-Patiño3,4,4, Carolina Sotelo4, Oscar Arrieta5, Lucia Zatarain-Barrón5, Camila Ordoñez4, Elvira Jaller6, Leonardo Rojas7, Alessandro Russo8, Diego de Miguel-Pérez9, Christian Rolfo9, Andrés F Cardona.   

Abstract

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor's molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.

Entities:  

Keywords:  KRAS; MET; biomarker; directed therapy; genomic profiling; non-small-cell lung cancer; resistance; targeted therapy; tumor genomics

Mesh：

Substances：

Year:  2022        PMID： 35098800      PMCID： PMC8808025          DOI： 10.1177/17534666211066064

Source DB:  PubMed          Journal:  Ther Adv Respir Dis        ISSN： 1753-4658            Impact factor:   4.031


  199 in total

1.  Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.

Authors:  Gonzalo Recondo; Magda Bahcall; Liam F Spurr; Jianwei Che; Biagio Ricciuti; Giulia C Leonardi; Ying-Chun Lo; Yvonne Y Li; Giuseppe Lamberti; Tom Nguyen; Marina S D Milan; Deepti Venkatraman; Renato Umeton; Cloud P Paweletz; Adem Albayrak; Andrew D Cherniack; Kristin S Price; Stephen R Fairclough; Mizuki Nishino; Lynette M Sholl; Geoffrey R Oxnard; Pasi A Jänne; Mark M Awad
Journal:  Clin Cancer Res       Date:  2020-02-07       Impact factor: 12.531

2.  Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Authors:  F Michael Yakes; Jason Chen; Jenny Tan; Kyoko Yamaguchi; Yongchang Shi; Peiwen Yu; Fawn Qian; Felix Chu; Frauke Bentzien; Belinda Cancilla; Jessica Orf; Andrew You; A Douglas Laird; Stefan Engst; Lillian Lee; Justin Lesch; Yu-Chien Chou; Alison H Joly
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

3.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

Authors:  Patrick C Ma; Ramasamy Jagadeeswaran; Simha Jagadeesh; Maria S Tretiakova; Vidya Nallasura; Edward A Fox; Mark Hansen; Erik Schaefer; Katsuhiko Naoki; Alan Lader; William Richards; David Sugarbaker; Aliya N Husain; James G Christensen; Ravi Salgia
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

4.  Coexpression of c-Met and Notch-1 correlates with poor prognosis in resected non-small-cell lung cancer.

Authors:  Ximing Wang; Na Song; Ye Zhang; Ying Cai; Yunpeng Liu; Xiujuan Qu; Zhi Li; Danni Li; Kezuo Hou; Jian Kang; Xuejun Hu
Journal:  Tumour Biol       Date:  2015-04-14

5.  Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.

Authors:  Marie Mayenga; Jean-Baptiste Assié; Isabelle Monnet; Marie-Ange Massiani; Laure Tabeze; Sylvie Friard; Séverine Fraboulet; Anne-Cécile Métivier; Christos Chouaïd; Leïla Zemoura; Elisabeth Longchampt; Céline Callens; Samia Melaabi; Louis-Jean Couderc; Hélène Doubre
Journal:  Lung Cancer       Date:  2020-09-16       Impact factor: 5.705

6.  HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.

Authors:  Thomas Bachleitner-Hofmann; Mark Y Sun; Chin-Tung Chen; Laura Tang; Lin Song; Zhaoshi Zeng; Manish Shah; James G Christensen; Neal Rosen; David B Solit; Martin R Weiser
Journal:  Mol Cancer Ther       Date:  2008-10-30       Impact factor: 6.261

7.  Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.

Authors:  Valentina Martin; Cristina Chiriaco; Chiara Modica; Anna Acquadro; Marco Cortese; Francesco Galimi; Timothy Perera; Loretta Gammaitoni; Massimo Aglietta; Paolo M Comoglio; Elisa Vigna; Dario Sangiolo
Journal:  Br J Cancer       Date:  2019-02-06       Impact factor: 7.640

8.  Cancer Vaccines: Research and Applications.

Authors:  Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2019-07-24       Impact factor: 6.639

9.  Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

Authors:  S Dearden; J Stevens; Y-L Wu; D Blowers
Journal:  Ann Oncol       Date:  2013-05-30       Impact factor: 32.976

Review 10.  Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.

Authors:  Swapnil Rajurkar; Isa Mambetsariev; Rebecca Pharaon; Benjamin Leach; TingTing Tan; Prakash Kulkarni; Ravi Salgia
Journal:  J Clin Med       Date:  2020-06-15       Impact factor: 4.241
View more
  2 in total

Review 1.  Current treatments for non-small cell lung cancer.

Authors:  Qianqian Guo; Liwei Liu; Zelong Chen; Yannan Fan; Yang Zhou; Ziqiao Yuan; Wenzhou Zhang
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

Review 2.  MET alterations in advanced pulmonary sarcomatoid carcinoma.

Authors:  Chen Gong; Huihua Xiong; Kai Qin; Jianhua Wang; Yi Cheng; Jing Zhao; Jing Zhang
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.